Internationale Publikationen
Hier stellen wir eine Auswahl wissenschaftlicher Veröffentlichungen zur Verfügung, die im Zusammenhang mit der IOZK-Immuntherapie stehen.
Sie können mit Hilfe der Filter eine Auswahl nach Tumorarten und Methoden treffen, oder Suchbegriffe eingeben.
Combinatorial strategies for alleviation of tumor-associated immune suppression and therapeutic vaccination against ovarian cancer
A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma
Reirradiation and hyperthermia for radiation-associated sarcoma
Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of pro-inflammatory cytokines by dendritic cells and macrophages
Prostate cancer immunotherapy
Dendritic cell (DC) vaccination with low dose temozolomide phase I/II trial in melanoma patients: Preliminary data on peripheral blood regulatory t-cells (Treg) and DC-TEM8 expression modulations.
Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
Sipuleucel-T: autologous cellular immunotherapy for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer
Recent advances in immunotherapy for the treatment of prostate cancer
Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
Pilot immunotherapy trial in high-risk pediatric sarcomas.
Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine
Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design